- 2025,07,14
Securities code: 603811
Securities abbreviation: sincerity pharmaceutical
Semi annual performance forecast of Zhejiang Zhencheng Pharmaceutical Co., Ltd. in 2025
The board of directors and all directors of the company guarantee that the contents of this announcement are free from any false records, misleading statements or major omissions, and bear legal responsibility for the authenticity, accuracy and completeness of its contents. Important content tips:
1. The specific application of the performance forecast: the company achieved profits, and the net profit increased by more than 50% compared with the same period of last year.
2. The expected profit of the company is 107.06 million yuan to 118.53 million yuan, with a year-on-year increase of 40.00% to 55.00%.
3. After deducting non recurring profit and loss events, the company's performance is expected to make a profit of 106.25 million yuan to 113.45 million yuan, with a year-on-year increase of 47.40% to 57.40%.
1、Performance forecast of the current period
（1） Performance forecast period: January 1st, 2025 to June 30th, 2025.
（2） Performance forecast
1. According to the preliminary calculation of the financial department, the net profit attributable to the shareholders of the listed company is expected to reach 107.06 million yuan to 118.53 million yuan in the half year of 2025, which will increase by 30.59 million yuan to 42.06 million yuan compared with the same period of last year, with a year-on-year increase of 40.00% to 55.00%.
2. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 106.25 million yuan to 113.45 million yuan, an increase of 34.17 million yuan to 41.37 million yuan, or 47.40% to 57.40% year on year, compared with the same period of last year.
（3） The expected performance of the company has not been audited by certified public accountants.
2、 Performance in the same period of last year
（1） Total profit: 87.3491 million yuan. Net profit attributable to shareholders of the listed company: 76.4655 million yuan. Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses: 72.0779 million yuan.
（2） Earnings per share: 0.23 yuan.
3、 Main reasons for performance increase in the current period
（1） The company's sales of joint drugs continued to grow;
（2） Loss reduction of loss making subsidiaries in the previous year.
4、 Risk tips
At present, the company has not found any other uncertain factors that may have a significant impact on the content of this performance forecast.
5、 Other notes
This performance forecast has not been audited by a certified public accountant. The above estimates are the results of the preliminary prediction of the company's financial department. The specific and accurate financial data are subject to the 2025 semi annual report officially disclosed by the company. The company reminds investors to pay attention to the information publicly disclosed by the company and pay attention to investment risks. It is hereby announced.
Board of directors of Zhejiang Zhencheng Pharmaceutical Co., Ltd
July 13, 2025